Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
News|Articles|December 22, 2025
Year In Review: Cover Stories of 2025
Listen
0:00 / 0:00
Key Takeaways
- Dermatology Times published articles in 2025 on diverse topics, including chronic hand eczema, vitiligo, melasma, and rosacea, reflecting ongoing advancements in dermatological care.
- The articles address gender leadership, neuroinflammatory mechanisms in steroid withdrawal, and visible light protection strategies, showcasing the breadth of dermatological research.
Advertisement
References
- Zirwas M, Dermatology Times Staff. State-of-the-state update: chronic hand eczema. News article. Dermatology Times. Published January 10, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/state-of-the-state-update-chronic-hand-eczema - Urbonas R, Jilani S, Cohen B. Vitiligo, melasma, PIH, and albinism: clinical update and emerging therapies. News article. Dermatology Times. Published February 10, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/vitiligo-melasma-pih-and-albinism-clinical-update-and-emerging-therapies - Andrus E, Hebebrand M. Bridging the gender gap: women leading the way. News article. Dermatology Times. Published March 18, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/bridging-the-gender-gap-women-leading-the-way - Hebebrand M. Rosacea: progress, challenges, and the road ahead. News article. Dermatology Times. Published April 14, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/rosacea-progress-challenges-and-the-road-ahead - Mestari Z, Cohen B. Topical steroid withdrawal: uncovering neuroinflammatory mechanisms. News article. Dermatology Times. Published May 6, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/topical-steroid-withdrawal-uncovering-neuroinflammatory-mechanisms - Dumbuya H. Visible light protection: needs and strategies for diverse patients. News article. Dermatology Times. Published June 3, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/visible-light-protection-needs-and-strategies-for-diverse-patients - Negbenebor N. Below the surface: dermatologic procedures for hidradenitis suppurativa. News article. Dermatology Times. Published July 17, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/below-the-suface-dermatologic-procedures-for-hidradenitis-suppurativa - Lal K. Recognizing the hidden burdens of pediatric psoriasis. News article. Dermatology Times. Published August 18, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/recognizing-the-hidden-burdens-of-pediatric-psoriasis - Miller B, Downing C. Balancing cure and cosmesis in Mohs surgery. News article. Dermatology Times. Published September 15, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/balancing-cure-and-cosmesis-in-mohs-surgery - Foroohar T, Damsky W, Leventhal J. Dermatology steps forward in onco-skin management. News article. Dermatology Times. Published October 9, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/dermatology-steps-forward-in-onco-skin-management - Lang D, Issa N. Cracking the code of chronic spontaneous urticaria: evolving care by allergists and dermatologists. News article. Dermatology Times. Published September 23, 2025. Accessed December 17, 2025.
https://www.dermatologytimes.com/view/deciphering-chronic-spontaneous-urticaria-evolving-care-by-allergists-and-dermatologists - Hebebrand M. Transformative advances this year and beyond. News article. Dermatology Times. Published December 11, 2025. Accessed December 17, 2025. https://www.dermatologytimes.com/view/transformative-advances-this-year-and-beyond
Advertisement
Related to this article
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.
Advertisement
Advertisement
Trending on Dermatology Times
1
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
2
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
5